Human Fas ligand extracellular domain (hFasLECD) is a soluble protein agent with significant relevance to medicine because of the immunologically essential functions of parental membrane-bound Fas ligand (CD95L, CD178) in the human body. This paper aimed to overview the current status of the studies focused on hFasLECD, ranging from its fundamental molecular properties and biological activity to its potential as a novel, practical cell death-inducing therapeutics or a diseases biomarker. The main part of this review was divided into four sections, the background of biological functions of human Fas ligand, the fundamental biochemical characteristics of hFasLECD, the production of engineered hFasLECD derivatives, and the potential of hFasLECD for medical applications. The translation of hFasLECD into an established agent in medicine is in progress, based on the clinical use-oriented research works in the relevant fields of basic science and engineering.
Citation: Michiro Muraki. Human Fas ligand extracellular domain: current status of biochemical characterization, engineered-derivatives production, and medical applications[J]. AIMS Medical Science, 2022, 9(4): 467-485. doi: 10.3934/medsci.2022025
Human Fas ligand extracellular domain (hFasLECD) is a soluble protein agent with significant relevance to medicine because of the immunologically essential functions of parental membrane-bound Fas ligand (CD95L, CD178) in the human body. This paper aimed to overview the current status of the studies focused on hFasLECD, ranging from its fundamental molecular properties and biological activity to its potential as a novel, practical cell death-inducing therapeutics or a diseases biomarker. The main part of this review was divided into four sections, the background of biological functions of human Fas ligand, the fundamental biochemical characteristics of hFasLECD, the production of engineered hFasLECD derivatives, and the potential of hFasLECD for medical applications. The translation of hFasLECD into an established agent in medicine is in progress, based on the clinical use-oriented research works in the relevant fields of basic science and engineering.
Human Fas ligand
Extracellular domain of hFasL
Natural killer
Soluble hFasL
Single chain variable fragment
Thymus-derived
Tumor necrosis factor
| [1] | Takahashi T, Tanaka M, Inazawa J, et al. (1994) Human Fas Ligand: gene structure, chromosomal location and species specificity. Int Immunol 6: 1567-1574. https://doi.org/10.1093/intimm/6.10.1567 |
| [2] | Fairley S, Lowy-Gallego E, Perry E, et al. (2020) The international genome sample resource (IGSR) collection of open human genomic variation resources. Nucleic Acids Res 48: D941-D947. https://doi.org/10.1093/nar/gkz836 |
| [3] | Alderson MR, Tough TW, Davis-Smith T, et al. (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 181: 71-77. https://doi.org/10.1084/jem.181.1.71 |
| [4] | Nagata S (1999) Fas ligand-induced apoptosis. Annu Rev Genet 33: 29-55. https://doi.org/10.1146/annurev.genet.33.1.29 |
| [5] | Green DR, Ferguson TA (2001) The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2: 917-924. https://doi.org/10.1038/35103104 |
| [6] | Risso V, Lafont E, Le Gallo M (2022) Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases. Cell Death Dis 13: 248. https://doi.org/10.1038/s41419-022-04688-x |
| [7] | Herrero R, Kajikawa O, Matute-Bello G, et al. (2011) The biological activity of FasL in human and mouse lungs is determined by the structure of its stalk region. J Clin Invest 121: 1174-1190. https://doi.org/10.1172/JCI43004 |
| [8] | Suda T, Hashimoto H, Tanaka M, et al. (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186: 2045-2050. https://doi.org/10.1084/jem.186.12.2045 |
| [9] | Malleter M, Tauzin S, Bessede A, et al. (2013) CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res 73: 6711-6721. https://doi.org/10.1158/0008-5472.CAN-13-1794 |
| [10] | Jeong D, Kim HS, Kim HY, et al. (2021) Soluble Fas ligand drives autoantibody-induced arthritis by binding to DR5/TRAIL-R2. eLife 10: e48840. https://doi.org/10.7554/eLife.48840 |
| [11] | Tiffiney EA, Coombes JL, Legembre P, et al. (2022) Cleaved CD95L perturbs in vitro macrophages responses to Toxoplasma gondii. Microbes Infect 24: 104952. https://doi.org/10.1016/j.micinf.2022.104952 |
| [12] | Liu W, Ramagopal U, Cheng H, et al. (2016) Crystal structure of the complex of human FasL and its decoy receptor DcR3. Structure 24: 2016-2023. https://doi.org/10.1016/j.str.2016.09.009 |
| [13] | Muraki M (2018) Development of expression systems for the production of recombinant human Fas ligand extracellular domain derivatives using Pichia pastoris and preparation of the conjugates by site-specific chemical modifications: A review. AIMS Bioengineer 5: 39-62. https://doi.org/10.3934/bioeng.2018.1.39 |
| [14] | Muraki M (2014) Disulfide-bridged proteins with potential for medical applications: therapeutic relevance, sample preparations and structure-function relationships. Integr Mol Med 1: 38-56. https://doi.org/10.15761/IMM.1000109 |
| [15] | Gasteiger E, Hoogland C, Gattiker A, et al. (2005) Protein identification and analysis tools on ExPASy server. The Proteomics Protocols Handbook.Humana Press 571-607. https://doi.org/10.1385/1-59259-890-0:571 |
| [16] | Schneider P, Bodmer JL, Holler N, et al. (1997) Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol Chem 272: 18827-18833. https://doi.org/10.1074/jbc.272.30.18827 |
| [17] | Muraki M (2006) Secretory expression of synthetic human Fas ligand extracellular domain gene in Pichia pastoris: influences of tag addition and N-glycosylation site deletion, and development of a purification method. Prot Expr Purif 50: 137-146. https://doi.org/10.1016/j.pep.2006.08.006 |
| [18] | Muraki M (2008) Improved secretion of human Fas ligand extracellular domain by N-terminal part truncation in Pichia pastoris and preparation of the N-linked carbohydrate chain trimmed derivative. Prot Expr Purif 60: 205-213. https://doi.org/10.1016/j.pep.2008.03.027 |
| [19] | Holler N, Tardivel A, Kovacsovics-Bankowski M, et al. (2003) Two adjacent Trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 23: 1428-1440. https://doi.org/10.1128/MCB.23.4.1428-1440.2003 |
| [20] | Shiraishi T, Suzuyama K, Okamoto H, et al. (2004) Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif. Biochem Biophys Res Commun 322: 197-202. https://doi.org/10.1016/j.bbrc.2004.07.098 |
| [21] | Eisele G, Roth P, Hasenbach K, et al. (2011) APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol 13: 155-164. https://doi.org/10.1093/neuonc/noq176 |
| [22] | Verbrugge I, Wissink EHJ, Rooswinkel RW, et al. (2009) Combining radiotherapy with APO010 in cancer treatment. Clin Cancer Res 15: 2031-2038. https://doi.org/10.1158/1078-0432.CCR-08-2125 |
| [23] | Jandu H, Nielsen A, Brunner N, et al. (2020) Characterization of resistance to a recombinant hexameric Fas-ligand (APO010) in human cancer cell lines. Exp Hematol 87: 33-41. https://doi.org/10.1016/j.exphem.2020.06.005 |
| [24] | Tanaka M, Suda T, Yatomi T, et al. (1997) Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol 158: 2303-2309. |
| [25] | Orbach A, Rachmilewitz J, Shani N, et al. (2010) CD40-FasL and CTLA-4-FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling. Am J Pathol 177: 3159-3168. https://doi.org/10.2353/ajpath.2010.100301 |
| [26] | Muraki M (2014) Improved production of recombinant human Fas ligand extracellular domain in Pichia pastoris: yield enhancement using disposable culture-bag and its application to site-specific chemical modifications. BMC Biotechnol 14: 19. https://doi.org/10.1186/1472-6750-14-19 |
| [27] | Muraki M (2016) Preparation of a functional fluorescent human Fas ligand extracellular domain derivative using a three-dimensional structure guided site-specific fluorochrome conjugation. SpringerPlus 5: 997. https://doi.org/10.1186/s40064-016-2673-8 |
| [28] | Muraki M, Hirota K (2017) Site-specific chemical conjugation of human Fas ligand extracellular domain using trans-cyclooctene-methyltetrazine reactions. BMC Biotechnol 17: 56. https://doi.org/10.1186/s12896-017-0381-2 |
| [29] | Muraki M, Hirota K (2019) Site-specific biotin-group conjugate of human Fas ligand extracellular domain: preparation and characterization of cell-death-inducing activity. Curr Top Pep Prot Res 20: 17-24. |
| [30] | Berger RML, Weck JM, Kempe SM, et al. (2021) Nanoscale FasL organization on DNA origami to decipher apoptosis signal activation in cells. Small 17: 2101678. https://doi.org/10.1002/smll.202101678 |
| [31] | Koshkina N, Yang Y, Kleinerman E (2020) The Fas/FasL signaling pathway: its role in the metastasic process and as a target for treating osteosarcoma lung metastases. Adv Exp Med Biol 1258: 177-187. https://doi.org/10.1007/978-3-030-43085-6_12 |
| [32] | Muraki M (2020) Sensitization to cell death induced by soluble Fas ligand and agonistic antibodies with exogenous agents: A review. AIMS Med Sci 7: 122-203. https://doi.org/10.3934/medsci.2020011 |
| [33] | He Y, van Bommel PE, Samplonius DF, et al. (2017) A versatile pretargeting approach for tumor-selective delivery and activation of TNF superfamily members. Sci Rep 7: 13301. https://doi.org/10.1038/s41598-017-13530-w |
| [34] | Zhao H, Woodward KB, Shirwan H, et al. (2013) Posttransplantation systemic immunomodulation with SA-FasL-engineered donor splenocytes has robust efficacy in preventing cardiac allograft rejection in mice. Transplant Proc 45: 1805-1807. https://doi.org/10.1016/j.transproceed.2013.01.049 |
| [35] | Skoumal M, Woodward KB, Zhao H, et al. (2019) Localized immune tolerance from FasL-functionalized PLG scaffolds. Biomaterials 192: 271-281. https://doi.org/10.1016/j.biomaterials.2018.11.015 |
| [36] | Nair PM, Flores H, Gogineni A, et al. (2015) Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proc Natl Acad Sci U S A 112: 5679-5684. https://doi.org/10.1073/pnas.1418962112 |
| [37] | Gregory-Ksander M, Marshak-Rothstein A (2021) The FasLane to ocular pathology-metalloproteinase cleavage of membrane-bound FasL determines FasL function. J Leukoc Biol 110: 965-977. https://doi.org/10.1002/JLB.3RI1220-834R |
| [38] | Rogge M, Yin XT, Godfrey L, et al. (2015) Therapeutic use of soluble Fas ligand ameliorates acute and recurrent herpetic stromal keratitis in mice. Invest Ophthalmol Vis Sci 56: 6377-6386. https://doi.org/10.1167/iovs.15-16588 |
| [39] | Muraki M (2022) Soluble Fas ligand, soluble Fas receptor, and decoy receptor 3 as disease biomarkers for clinical applications: A review. AIMS Med Sci 9: 98-267. https://doi.org/10.3934/medsci.2022009 |
| [40] | Benmebarek MR, Karches CH, Cadilha BL, et al. (2019) Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci 20: 1283. https://doi.org/10.3390/ijms20061283 |
| [41] | Khawar MB, Sun H (2021) CAR-NK cells: from natural basis to design for kill. Front Immunol 12: 707542. https://doi.org/10.3389/fimmu.2021.707542 |
| [42] | Pang Z, Wang Z, Li F, et al. (2022) Current progress of CAR-NK therapy in cancer treatment. Cancers 14: 4318. https://doi.org/10.3390/cancers14174318 |
| [43] | Wallach-Dayan SB, Petukhov D, Ahdut-HaCohen R, et al. (2021) sFasL-the key to a riddle: Immune responses in aging lung and disease. Int J Mol Sci 22: 2177. https://doi.org/10.3390/ijms22042177 |
Figures(1) / Tables(2)
Michiro Muraki. Human Fas ligand extracellular domain: current status of biochemical characterization, engineered-derivatives production, and medical applications[J]. AIMS Medical Science, 2022, 9(4): 467-485. doi: 10.3934/medsci.2022025
DownLoad: